JPMorgan analyst Anupam Rama established a $9 December 2025 price target on shares of Sage Therapeutics (SAGE) while keeping a Neutral rating on the name. The price target accounts for peaks sales of Zurzuvaue in depression nd no platform value given the company’s multiple pipeline setbacks, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- SAGE Therapeutics Faces Legal Challenges: Potential Impact on Financial Stability and Growth
- Hold Rating for SAGE Therapeutics: Inventory Challenges and Strategic Prospects
- SAGE Therapeutics’ Earnings Call: ZURZUVAE’s Success Amid Challenges
- Sage Therapeutics price target lowered to $12 from $14 at Scotiabank
- Sage Therapeutics price target lowered to $7 from $9 at Baird